Immunic, inc. to host virtual r&d day today to provide an update on the preclinical and clinical development of imu-935, a potentially best-in-class rorΓt inverse agonist

New york, july 12, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that it will host a virtual r&d day today at 4:00 pm et. immunic's management and zuoming sun, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking